Background. Thymomas are a heterogeneous group of tumors. Treatment of
invasive lesions is not well standardized. The aim of this study is t
o propose a clinicopathologically based protocol for multimodality the
rapy. Methods. Between 1965 and 1988, we operated on 83 patients with
thymoma who did not receive standardized adjuvant therapy. In 1989, on
the basis of the retrospective analysis of the data, we started a mul
timodality therapy protocol and used it for 65 patients. Twelve patien
ts had medullary thymoma (11 stage I and 1 stage II), 13 had mixed typ
e (6 stage I and 7 stage II), and 40 had cortical thymoma (4 stage I,
11 stage II, 12 stage III, and 13 stage IV). We considered three group
s. Group I(n = 18 patients), benign thymoma, included stage I and II m
edullary and stage I mixed thymomas; radical resection with no adjuvan
t therapy was performed. Group II (n = 22), invasive thymoma, included
stage I and II cortical and stage II mixed thymomas; postoperative ch
emotherapy plus radiotherapy was always administered. Group III (n = 2
5), malignant thymoma, comprised stage III and IV cortical thymomas an
d stage III mixed thymomas; resectable stage III lesions were removed,
and highly invasive stage III and stage IV lesions underwent biopsy,
neoadjuvant chemotherapy, and surgical resection; postoperative chemot
herapy and radiotherapy was administered to all patients. Results. The
8-year survival rate for patients in stages I, II, III, and IV was 95
%, 100%, 92%, and 68%, respectively. Patients with medullary thymoma h
ad a 92% 8-year survival rate; those with mixed type, 100%; and those
with cortical thymoma, 85%. Group I had an 8-year survival rate of 94%
; group II, 100%; and group III, 76%. Survival was compared with that
of patients operated on before 1989: differences were not significant
for group I; survival improved in group II (100% versus 81%; p = not s
ignificant); and group III showed significant improvement (76% versus
43%; p < 0.049). Conclusions. Multimodality treatment with neoadjuvant
chemotherapy and adjuvant chemotherapy plus radiotherapy may improve
the results of radical resection and the survival of patients with inv
asive and malignant thymoma. (C) 1997 by The Society of Thoracic Surge
ons.